Marijuana Sector News

0 2276

$VNNYF Appoints Mr. Facundo Bacardi to Board of Directors

Vinergy Resources Ltd. (“Vinergy” or the “Company”) (CSE:VIN)(VIN.CN)(VNNYF) in conjunction with its proposed acquisition of MJ Biopharma (announced December 14, 2016) is pleased to announce it has appointed Mr. Facundo Bacardi to its Board of Directors effective immediately.

Mr. Bacardi is a member of the family that owns and controls Bacardi Ltd., a worldwide liquor manufacturer and distributor. From 1979 to 1991, he was the head of Bacardi’s manufacturing and distribution division for Nassau, Brazil, Trinidad and Central America. Since 1990, Mr. Bacardi has served as a Director of Suramericana de Inversiones, S.A., an investment company located in Panama. He is a founding shareholder of JSM Capital Holding Corp., a shareholder and Director of Global Arena Holdings, Inc. Mr. Bacardi is also on the Honorary Consul for the Bahamas in Panama.

“We are excited to have someone of Mr. Bacardi’s calibre and pedigree join our team. We look forward to working closely with him on our strategy to roll out products and technologies internationally,” said Mr. Kent Deuters, CEO of MJ Biopharma…[continue reading]


Click Here Now To Read Full Release


$UBQU Gives Shareholders Overview of First Quarter Progress

DENVER, CO–(Marketwired – Mar 9, 2017) – Ubiquitech Software Corp. (OTC PINK : UBQU) and the CEO of HempLife Today™ wants all shareholders and the public to have a solid overview of the Company’s first quarter progress along with projects and projections moving forward. The Company wants shareholders to know it is in a strong financial position with experienced management at the helm, creative talent on its staff, and seasoned legal and accounting experts to ensure growth.

“Through this press release it is the company’s desire to communicate directly with the shareholders and the public interested in our Company,” said James Ballas, CEO. “Shareholders should be aware that there is never a wasted day or opportunity for the Company. In addition, we always want our shareholders to know that we value them and the trust that they give us through their becoming shareholders. This is very important to us, and in everything we do we keep this in mind.”

The Company is proud to report the following…[continue reading]


Click Here Now To Read Full PR


Pursuant to an agreement between MAPH and Ubiquitech Software Corp., we were hired for a period beginning November 11 2016 and ending May 11, 2017 to publicly disseminate information about (UBQU) including on the Website and other media including Facebook and Twitter. We are being paid $0 (CASH) for or were paid “10 million” shares of restricted common shares. Pursuant to an agreement between MAPH and Vinergy Resources, we were hired for a period of 2 months to publicly disseminate information about (VNNYF) including on the Website and other media including Facebook and Twitter. We are being paid $120,000 (CASH) for or “ZERO” shares of restricted or unrestricted common shares. We own zero shares of (VNNYF) which we purchased in the open market. We may buy or sell additional shares of (UBQU,VNNYF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

0 1011

HempLife Today CEO Gives Shareholders Overview of First Quarter Progress and Projections Moving Forward

Ubiquitech Software Corp. ( OTC PINK : UBQU ) and the CEO of HempLife Today™ wants all shareholders and the public to have a solid overview of the Company’s first quarter progress along with projects and projections moving forward. The Company wants shareholders to know it is in a strong financial position with experienced management at the helm, creative talent on its staff, and seasoned legal and accounting experts to ensure growth.

“Through this press release it is the company’s desire to communicate directly with the shareholders and the public interested in our Company,” said James Ballas, CEO. “Shareholders should be aware that there is never a wasted day or opportunity for the Company. In addition, we always want our shareholders to know that we value them and the trust that they give us through their becoming shareholders. This is very important to us, and in everything we do we keep this in mind.”

The Company is proud to report the following:

We continue to be 100% committed to the name and symbol change that best reflects our business and that will successfully represent us well into the future. This has been a very intensive legal process and the Company wants all shareholders to understand that this is a process and that the Company will keep shareholders informed of any and all pertinent information regarding this important step. Again, the company is 100% committed to this, but in the meantime will continue to update shareholders on the progress of the Company, with specific reference to revenue and profits, achievements and goals, and additional important fundamental developments and milestones.

The Company continues to add new customers at an accelerated rate as our sales platforms continue to grow. These platforms include extensive Internet, SEO, Social Media, Blogs, Affiliates, and traditional marketing that all work together to educate the public and create more and more new customers at an exponential rate. The Company alerts all shareholders that they can “search” for HempLife Today™ and our CannazALL™ brand of CBD products to see the footprint we continue to expand.

The Company continues to develop some of the finest CBD products derived from Hemp and offers them through our CannazALL™ brand. These products now include First-cut oils from our purpose grown Hemp plants rich in CBD and through our NanoTech Infusion Process™ are infused with over 200% more important plant Terpenes and other natural Hemp plant materials, giving our products the superior “entourage effect” that is desired. CannazALL™ products currently include:

Tinctures, Concentrates, GelCaps, Mixable Powder, Skin Salve, E-juice, and new dabbing Honey, with more to come in 2017.

The Company continues to keep its prices for CannazALL™ CBD products as low as possible through our discount coupon codes, and our generous Referral and Rebate programs. In fact, every customer has the opportunity to get free CannazALL™ products simply by referring others who then make purchases, plus earn Rebates on every dollar spent. These programs are extremely popular and we continue, through advanced programming, to make these programs easier and more user friendly so that more HempLife Today™ customers can take advantage of these opportunities and to add customers to our customer base.

The company continues to board new customers at low acquisition rates thus saving precious revenue on expensive advertising. Through 3rd quarter of 2016 to the present, the Company is able to acquire new customers at almost 90% less in advertising costs than it did in the first 2 years of operation. This trend will continue and will also improve.

The Company is also finishing up the freshening of the main Websites of www.HempLifeToday.com and www.HempLife.com with new images, copy, and special offers that make navigation of the sites more educational and easier for new and existing customers. The Company will also be unveiling an exciting new HempLife Today™ logo in the near future and this will be announced as well.

The Company has been operating under our Rapid Ship order processing since the first week in February and all orders are shipped within 24 hours via USPS Priority Mail. This was achieved through extensive custom programming so that most orders are delivered within 3-5 business days of the actual order being placed. The Company knows that fast shipping and delivery are vital to our customers.

0 1939

$IMLFF to Present at the 29th Annual ROTH Conference

 

InMed Pharmaceuticals, Inc.(“InMed”) (CSE: IN; OTCQB: IMLFF) announces today that Eric A. Adams, Chief Executive Officer, will be presenting to U.S. institutional investors at the 29th Annual ROTH Conference, which is being held March 12-15, 2017, at the Ritz Carlton, Laguna Niguel, California.


Click Here Now To Read Full Release


List Of CBD Stocks To Watch

For a fairly new market, the Marijuana industry has been embracing unprecedented levels of growth over the past decade. The surge had every investor frantically logging in to their e-trade accounts trying to find the next big Marijuana stock. Although the previous focus of the medical companies was based on the harvesting of the THC component of Marijuana, many have recently discovered the true health benefits of Cannabidiol; a part of the plant that only holds its health benefits and not those that get you ‘high.’

Based on the attention the industry is getting, it seems fitting to highlight some of the most active CBD stocks to watch this year. Here are several CBD stocks on our own list…[continue reading]


Click Here To Read Full Article


 

$RMHB Acquire Upstate New York Facility as a Bottling Plant

Rocky Mountain High Brands, Inc. (RMHB), a fully reporting consumer goods company specializing in hemp-infused food and beverage products and a naturally high alkaline water announced today that it has entered into an agreement with L and H Resort Systems to acquire a former Catskill Mountain resort facility located on a natural spring. The Company plans to repurpose the resort into a Bottling and Canning Plant for Rocky Mountain High Brands…[continue reading]


Click Here Now To Read Full PR


Pursuant to an agreement between MAPH and InMedPharmaceuticals., we were hired for a period beginning February 24 2017 and ending April 24, 2017 to publicly disseminate information about (IMLFF) including on the Website and other media including Facebook and Twitter. We are being paid $40,000 (CASH) for and were paid “250,000” shares of restricted common shares of InMed Pharmaceuticals.We may buy or sell additional shares of (IMLFF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

1 2167

$UBQU Gives First Quarter Revenue Guidance

Ubiquitech Software Corp. (OTC PINK : UBQU), through its operating subsidiary HempLife Today™, is announcing first quarter revenue guidance. The company anticipates that revenues for the quarter ended February 28, 2017 will increase over 50% from $697,640 in the first quarter of last year to approximately $1,050,000. The revenue growth is due primarily to the continued acceptance and increased exposure of the HempLife Today™ product line.


Click Here Now To Read Full Release


The Hemp Boom Is Coming

Since growing hemp has been illegal for almost a full century, researchers have been unable to learn all the benefits associated with it. Currently, most states have an active hemp industry or have authorized hemp research. Hemp is a distinct variety of the cannabis plant but it is not the same as marijuana. Although hemp is commonly associated with marijuana, it should not be.

Industrial hemp and marijuana are two completely different plants, inside and out. Hemp contains a very small amount (less than 1%) of tetrahydrocannabinol (THC), the primary psychoactive ingredient in marijuana (the chemical that gets a user high). Legal marijuana has a much larger amount of THC (between 15%-30%).

Benefits of industrial hemp…[continue reading]


Click Here To Read Full Article


Legislator In Arizona Wants To Open The Doors To The Industrial Hemp Industry

Senator Sonny Borrelli, a Republican senator from Lake Havasu City sees economic opportunity in industrial hemp and wants to bring it into Arizona. Borrelli has sponsored a proposal to establish the groundwork for an industrial hemp industry in the state. If the measure is passed, Senate Bill 1337 would legalize the farming, sale, and distribution of industrial hemp. It would task the state’s agricultural department with oversight, regulation, and licensing of the industry. The bill passed 26-4 with bipartisan support in the Senate and is now in the House…[continue reading]


Click Here Now To Read Full Article


Pursuant to an agreement between MAPH and Ubiquitech Software Corp., we were hired for a period beginning November 11 2016 and ending May 11, 2017 to publicly disseminate information about (UBQU) including on the Website and other media including Facebook and Twitter. We are being paid $0 (CASH) for or were paid “10 million” shares of restricted common shares.We may buy or sell additional shares of (UBQU) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

1 15903
Jeff_Sessions_Legal_Marijuana

“Wait did I read that correctly?” you’re probably asking yourself, right? Mr. Sessions has seemingly been the thorn in the side of the legal marijuana movement and he’s been a topic of great debate for days now. But there may be some shining light ahead to put a bit more ease to those looking at this industry and in their favor. Yes, worries about this “great shift” in federal enforcement in states where recreational legalization has been granted may be able to breathe a little easier right now.

There’s been an immense amount of angst and paranoia with regard to what some have understood as a government crackdown on recreational use. U.S. Attorney General Jeff Sessions has had private discussions with a few Republican senators saying that he doesn’t plan to stray away from the Obama-placed policy of granting states the ability to enact their own marijuana laws for their residents.

Sessions has been a strong force to be reckoned with after he ordered a review of the “hands-off” policy that President Barack Obama previously had. But apparently Mr. Sessions has had a bit of a change of heart and in private conversations, has assured senators before he was confirmed that he didn’t have too much consideration about drastically changing the enforcement laws; even though he’s not a fan of the drug’s use.

Here are a few quotes from these informed senators:

“Nothing at this point has changed,” said Sen. Cory Gardner (R-Colo.)

“He told me he would have some respect for states’ right on these things. And so I’ll be very unhappy if the federal government decides to go into Colorado and Washington and all of these places. And that’s not the [what] my interpretation of my conversation with him was. That this wasn’t his intention.”

-Sen. Rand Paul (R-Ky)

“We respectfully request that you uphold DOJ’s existing policy regarding states that have implemented strong and effective regulations for recreational use. It is critical that states continue to implement these laws.”

-Sens. Elizabeth Warren (D-Mass.) & Lisa Murkowski (R-Alaska)

“Do they really respect states’ rights? Then you should respect all of them, not just pick and choose the ones that you want to support or not. Many states have gone not only the path of Nevada of recreational marijuana but medical marijuana. How can you pick or choose one or another?”

-Sen Catherine Cortez Masto (D-Nevada)

A group of bipartisan senators also had submitted a letter on Thursday that pushed for Sessions to keep the Obama-era policy intact in order to let states decide on how to implement recreational marijuana laws. Sen. Warren and Sen. Murkowski lead the effort; both of who are from states who’s already put legalized marijuana laws in place.

To date, 8 states and Washington, D.C. have laws in place that legalize marijuana for recreational use. Most senators who signed on the letter are from those states with Murkowski being the only Republican. The others include:

Sen. Patty Murray of Washington
Sen. Ron Wyden of Oregon
Sen. Jeff Merkley of Oregon
Sen. Maria Cantwell of Washington
Sen. Ed Markey of Massachusetts
Sen. Brian Schatz of Hawaii
Sen. Catherine Cortez Masto of Nevada
Sen. Cory Booker of New Jersey
Sen. Michael Bennet of Colorado

The concern isn’t just among senators from those states but is an issue among many conservatives who are nervous about the GOP being selective about allowing the rights of states to supersede federal law.

“We’re concerned about some of the language that we’re hearing. And I think that conservatives who are for states’ rights ought to believe in states’ rights. I’m going to continue to advocate that the states should be left alone,” Paul said.

Sen. Gardner was even more direct with the opinion on Sessions’ comments, “He was talking about if there’s cartels involved in illegal operations, they’re going to crack down on that. That’s what everybody’s saying. I still haven’t heard Jeff Sessions say that. We obviously want to make sure we’re clear on what they’ve said.”

Despite the shake-up that Sessions almost single-handedly ignited with his comments about “not being a fan of expanded use of marijuana,” or how despite him being open to states passing laws that they choose, he made it a point to say, “it does remain a violation of federal law to distribute marijuana throughout any place in the United States, whether a state legalizes it or not,” senators like Murkowski seem unshaken. In fact Murkowski said that she wasn’t alarmed and is simply monitoring the DOJ closely, “It’s probably a little premature to try to predict what may or may not be coming out of the administration on this, so I think we just need to sit back and see.”

0 1857

$UBQU announces new CannazALL CBD Wax Dabbing Honey Available This Friday

Ubiquitech Software Corp. ( OTC PINK : UBQU ), is announcing its newest CannazALL™ CBD product derived from Hemp called “Honey” to be used with a wax dabbing Vape. The company believes this is the best dabbing product it has ever created and that both current, and new, customers will want to try, and continue to order, this potent and enjoyable new CannazALL™ product. In addition, the company is kicking off a new awareness campaign for this product March, April 3rd via in-house customer lists, social media, and other marketing platforms. The company expects sales to be brisk.

 


Click Here Now To Read Full PR



Jeff Sessions Marijuana Math: 2+2= Potato

Last week’s comments from Press Secretary Sean Spicer about recreational cannabis raised eyebrows but they are nothing compared to what United States Attorney General Jeff Sessions said this week.Sessions met with reporters and said that experts told him about violence in the cannabis industry. These experts also said the potency levels are unhealthy. Sessions also implied that state-level legalization was leading to increased youth consumption.

Alternative Facts Distort the Truth…[continue reading]

 


Click Here To Read Full Article


Nevada Keeps Date Set For Cannabis Sales In Spite Of Crackdown Warning

State officials recently said that Nevada still plans to launch recreational cannabis sales in July in spite of warnings of a federal restriction by the administration of President Donald Trump. Cannabis possession and sales are illegal under federal law, but Nevada voters decided in November to allow people age 21 or older to use pot recreationally. White House spokesman Sean Spicer recently said that the United States Justice Department will step up enforcement of federal laws restricting recreational cannabis. No immediate action accompanied the statement, came in response to a reporter’s question.

 


Click Here Now To Read Full Article


 

Pursuant to an agreement between MAPH and Ubiquitech Software Corp., we were hired for a period beginning November 11 2016 and ending May 11, 2017 to publicly disseminate information about (UBQU) including on the Website and other media including Facebook and Twitter. We are being paid $0 (CASH) for or were paid “10 million” shares of restricted common shares.We may buy or sell additional shares of (UBQU) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

0 1578

Form 8-K for MCIG, INC.


28-Feb-2017

Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits

Item 2.01 Completion of Acquisition or Disposition of AssetsOn February 23, 2017, mCig, Inc., a Nevada corporation (the “Company”), entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Stony Hill Corp., a Nevada corporation (“Stony Hill”). Pursuant to the terms and conditions of the Asset Purchase Agreement, the Company sold 80% of those certain assets that comprise the VitaCBD business (the “Assets”) to Stony Hill and issued an option (the “Option”) to Stony Hill to acquire the remaining 20% of assets related to the Assets for a minimum purchase price of $200,000. The VitaCBD business is primarily a line of cannabidiol (“CBD”) retail products available for purchase at vitacbd.com, which products include CBD tinctures, ejuices, edibles, islates, salves, waxes, oils and capsules, as well as related trade names, social media, accounts and other related assets. Information on the vitacbd.com website is not part of the disclosure on this Current Report on Form 8-K.

The purchase price the Company sold the Assets for was $850,000. The purchase price was comprised of $150,000 in cash and 350,000 shares of common stock of Stony Hill at $2.00, as may be adjusted. Initially, the Company will receive 200,000 shares of the common stock of Stony Hill at closing. Additionally, on May 24, 2017, Stony Hill is obligated to issue (the “Second Stock Issuance”) the remaining 150,000 shares of Stony Hill common stock or that number of shares of common stock of Stony Hill valued at $300,000, whichever has a lesser “Market Value,” defined as average of the closing prices for the common stock of Stony Hill on any quotation tier of the OTC Markets, as reported by the OTC Markets, for the 90 trading days subsequent to February 23, 2017. If the market value of the Second Issuance on the anniversary date of such issuance is greater than $300,000, the additional value shall be offset against of the sale price of the Option to sell the remaining 20% of assets related to the Assets.

If the average during any 7-day period during the first year following the Second Stock Issuance, the Market Value of the share of common stock of the Stony Hill owned by mCig is less than $550,000 (which amount represents the minimum target Market Value of the shares of common stock of Stony Hill held by mCig immediately following the issuance of shares of common stock of Stony Hill), then Stony Hill is obligated to issue to mCig that additional number of common stock of Stony Hill, on the one year anniversary date, to increase the Market Value of the total outstanding shares of common stock of Stony Hill held by mCig to $550,000, without the payment of any additional consideration.

In connection with the Asset Purchase Agreement, the Company also entered into a Lock-up Agreement dated February 23, 2017, with Stony Hill, pursuant to which the Company agreed to not resell any shares of common stock it received in connection with the Asset Purchase Agreement for a period of one year.

In connection with the Asset Purchase Agreement, the shares issued under the Second Stock Issuance are subject to a Security and Pledge Agreement, pursuant to which the Company pledged and granted a security interest in the shares issued under the Second Stock Issuance to Stony Hill to cover claims by Stony Hill against the Company that may arise under the terms and conditions of the Asset Purchase Agreement in the 90 days following the closing of the Asset Purchase Agreement.


 

Item 9.01 Financial Statements and Exhibits.(d) Exhibits:

Exhibit   Description

10.1      Asset Purchase Agreement, dated February 23, 2017, by and between Stony
          Hill Corp., a Nevada corporation, and mCig, Inc., a Nevada corporation.
10.2      Bill of Sale, Assignment and Assumption, dated February 23, 2017, by and
          between Stony Hill Corp., a Nevada corporation, and mCig, Inc., a Nevada
          corporation.
10.3      Assignment of Intellectual Property, dated February 23, 2017, made by
          mCig, Inc., a Nevada corporation.
10.4      Lock-up Agreement, dated February 23, 2017, by and between Stony Hill
          Corp., a Nevada corporation, and mCig, Inc., a Nevada corporation.
10.5      Security and Pledge Agreement, dated February 23, 2017, by and between
          Stony Hill Corp., a Nevada corporation, and mCig, Inc., a Nevada
          corporation.

 

4 9616

By Jason Spatafora @WolfofWeedSt

“I fear the Greeks, even those bearing gifts.”- Virgil

The DEA’s recent cannabis research expansion is a Harry Houdini inspired smoke show of misdirection all to set up the next trick; there I said it. While some view it as a positive first step, I tend to think it served a very deliberate function. Optically it played directly into expected vitriolic fallout from advocates, activists and media touts, all of which lined up to ignite their “DEA should reschedule cannabis” torches. In a “perfect world” scenario these people aren’t wrong, cannabis isn’t Heroin’s equal & 1+1=2, but just as fire cannot exist in a vacuum, neither can a rational cannabis debate. And while everyone on the side of reason is shouting in unison about rescheduling they failed to see that they might have just had their pockets picked. DEA’s policy statement that everyone seemed to ignore there are 33 words that have the potential to create the legal framework for the monopolization of Cannabis by means of an exclusionary application process.

Prologue – August 10th, 2016

Russ Baer, a staff coordinator for the Drug Enforcement Administration (DEA) media affairs wing gave a response to Steven Nelson of USNEWS.com via email. Nelson later shared a screen grab of the email via tweet. The statement made to him from this Drug Enforcement Administration staff coordinator read:

“Tomorrow morning (August 11th, 2016) the Drug Enforcement Administration will be making some important announcement regarding Marijuana related topics that will be published in the Federal Register. Because of your interest and/or prior engagement with the DEA on this subject, the DEA office of National Media Affairs is reaching out to you regarding these anticipated announcements.”

Over the next 24 hours social media was a blaze, with many people within the industry uncovering the fact that Rescheduling wouldn’t happen and that the DEA response would have to do with research. As expected, the incendiary scheduling of cannabis debate raged on into the following day.

August 11th, 2016

As expected, the Drug Enforcement Administration disappointed the advocates and activists of medical marijuana by not removing or rescheduling marijuana from its class 1 controlled substance status. Yet the DEA, in all of its benevolence, offered a consolation prize of sorts, by “deciding” to expand the study of Medical Marijuana for researchers, Universities & drug companies outside of the confines of a single federally legal facility. The facility, to refresh your memory is located at the University of Mississippi, (ranked 164th in Bio Sciences) and had up to this point been the sole research monopoly on legally grown marijuana, courtesy of the NIDA (National Institute on Drug Abuse).

DEA’s Misdirection Strategy

Over the next few days it seemed that every headline following the DEA’s deliberation was about the archaic rescheduling system & how cannabis is safer statistically than opiates that are schedule 2. Some media outlets went as far as to paint a “glass half full” picture. The LA Times for example did a piece titled “DEA ends its monopoly on marijuana growing for medical research.” The social reaction from cannabis enthusiasts, advocates and potrepreneurs from Main Street to Wall Street was as expected with everyone chiming in on social media to wag their fingers at the DEA. Representative Barbara Lee, a congresswoman from Oakland California stating via tweet “Politicians aren’t doctors or scientists. Marijuana research prohibitions are outdated, unscientific, & dangerous for those who need #MMJ.” As expected the rhetoric from the cannabis side was “The DEA is bad, the War on Drugs is a complete failure, Big Pharma is to blame,” so on and so forth.

IMG_8473

The people aren’t wrong on many of these points. The War in Drugs is a failure when considering addiction has been plateauing since its 1970 inception and US drug control spending is up 2000%, which to date stands at $1.5 trillion dollars. We can go on and on as to where that money went, what industries it created (prison industrial complex), the people it disproportionately targeted (minorities), but that’s a whole other article or book for that matter. Big Pharma however does have its trillion dollars hands in this story, but more on that later as I’ve digressed.

Not to go back and pick on the LA Times click-bate headline of “DEA ends its monopoly on marijuana growing for medical research,” but did it really end the monopoly? Let’s evaluate the idea. Yes, a monopoly is defined as “the exclusive possession or control of the supply or trade in a commodity or service.” The University of Mississippi was in fact in exclusive possession of the NIDA edict to legally grow marijuana and study it. On the surface the Monopoly has ended, but the reality is that we are just switching out the term Monopoly for an Oligarchy. Is an oligarchy any different than a monopoly in the sense that it’s just a smaller group carving out the biggest slices for themselves, eliminating competition by means of out maneuvering or outspending their opponent in an effort to influence policy such as this? Consider that the biggest lobby against the cannabis Industry is the pharmaceutical industry, yet they’re simultaneously studying cannabis for the purpose of synthesizing its many chemical compounds to create their high margin drugs.

Currently, their high margin bread and butter are the opioids for pain management such as OxyContin, Percocet and their generic versions of each. The drug companies are experts at isolating molecules from nature to create drugs that cost pennies to manufactures. In a zero sum game, cannabis is a direct threat to pharma companies, by snatching billions in profit and simultaneously causing billions in losses. Anti-cannabis lobbies would also be at risk as the pharmaceutical giants that feed them down on K Street would lose out on easy paydays. These anti-Marijuana lobbyists provide a micro look at the systemic problems within American politics illustrating how/why elected officials in Congress consistently vote against the interests of their collective constituency and bring forth carefully crafted bills or amendments like this one.

On the DEA’s policy statement and legal considerations section, under, legal applicable considerations it states.

“Second, as with any application submitted pursuant to section 823(a), in determining whether the proposed registrationwould be consistent with the public interest, among the factorsto be considered are whether the applicant has previous experience handling controlled substances in a lawful manner and whether the applicant has engaged in illegal activity involving controlled substances. In this context, illegal activity includes any activity in violation of the CSA (regardless of whether such activity is permissible under State law) as well as activity in violation of State or local law. While past illegal conduct involving controlled substances does not automatically disqualify an applicant, it may weigh heavily against granting the registration.”

Translation, grow marijuana even in a state where it’s legal and you are going to have a hard time becoming a manufacturer or researcher for the DEA’s new policy, thus excluding tier one cultivators in practice and likely creating a perpetual home for cannabis on the scheduling list. Prohibition’s end could very well be right around the corner, but the fear is in the form of legal medical marijuana at a Walgreens near you. I asked the DEA’s Russ Baer directly if the inserted language above in bold would be a non-starter for current cultivators wanting to become manufacturers as they are in clear Violation of CSA? In a written statement to Marijuana Stocks the DEA’s official response was:

“DEA is serious about facilitating marijuana research and that there is a lawful pathway for doing so. This DEA decision will facilitate increased research involving marijuana, within the framework of the law and U.S. treaty obligations, to enhance the drug’s supply available to researchers. The goal of this historic and monumental policy shift is to increase the amount and variety of marijuana available to researchers and make it easier for researchers to obtain marijuana as compared to current system under which marijuana must be obtained from NIDA. Growers must become registered with DEA, following the submission of an application, which DEA will evaluate in accordance with the CSA. Registered growers will need to comply with all CSA regulatory requirements, such as quotas, record keeping, order forms, and maintenance of control against diversion. Marijuana produced under this proposal may only be supplied to DEA-registered manufacturers and researchers, and only for purposes authorized by the CSA.

All potential new drugs, including drug products made from marijuana, are subject to the rigors of the drug approval process mandated by the Federal Food, Drug and Cosmetic Act (FDCA). This drug approval process requires that before a new drug is allowed to enter the U.S. market, it must be demonstrated through sound clinical trials to be both safe and effective for its intended uses,” stated Russ Baer of the Drug Enforcement Agency.

When asked if the inserted language also creates an unfair advantage for Pharma companies the response from the Drug Enforcement Administration circled back to the CSA (Controlled Substance Act) stating that the “DEA has adopted a new policy, consistent with the CSA and U.S. treaty obligations, under which additional entities may become registered with DEA to grow and distribute marijuana for research purposes. DEA will evaluate each application it receives to determine whether adding such applicant to the list of registered growers is necessary to provide an adequate and uninterrupted supply of marijuana to researchers in the U.S. In addition, applicants must demonstrate their ability to safely secure the drugs to prevent diversion, while abiding by the approved research protocol.”

The Controlled Substance Act

Everything points back to the Controlled Substance Act, a bill that was introduced into the Congress by Harley Staggers and took less than 6 weeks to get passed by the Senate and signed into law by President Richard M. Nixon. The signing of this document not only created the “War on Drugs,” but put an enforcement agency (DEA) in charge of Cannabis scheduling, circumventing the FDA in a move that creates an inter-agency firewall of sorts. The DEA’s position on why the FDA, who already regulates pharmaceutical drugs, isn’t in charge of marijuana rescheduling was point blank, “The Controlled Substances Act provides a mechanism for substances to be controlled (added to or transferred between schedules) or decontrolled (removed from control). The CSA provides roles for DEA and the FDA. Proceedings to add, delete, or change the schedule of a drug or other substance may be initiated by DEA, HHS, or by petition from any interested party. Once initiated, the process involves a deliberate and collaborative interagency exchange.”

IMG_8472

In Laymen’s terms CSA effectively says “DEA you’re in charge of this, FDA you’re in charge of that.” Unfortunately, Marijuana will never be completely removed from the scheduling list unless there is a major political overhaul in every branch of government, if and only if elected officials stop letting lobbies pour honey in their ears and money into campaigns. The reality from my perspective is that the DEA is a scapegoat, the perfect Boogey Man, simply because their job is to follow orders. They are soldiers in a sense, adhering to the guidelines of the Controlled Substance Act (CSA), a legal document crafted by a congress, molded in the image of benefactors, used to fuel a fake war and create cottage industries.

The DEA knows marijuana is safer than Oxy and that’s not speculation that’s a direct quote. They don’t want to go after the mother transporting medication to her sick child because they’re suffering from seizures. They want the dangerous individuals like El Chapo or the pill mills slinging Oxy off the streets. They have no interest in going after all cultivators following state law to the letter. Are there exceptions, of course! Does it make these comments directly from them any less true? No.
DEA’s direct position on which drug is more dangerous from a consumption standpoint as it relates to Cannabis vs OxyContin? “There were more than 47,000 drug overdose deaths in 2014, or approximately 129 per day, more than half (61 percent) of which involved either a prescription opioid or heroin. Marijuana meets the statuary criteria of a Scheduled I controlled substance, and has been determined to have a high abuse potential with no currently accepted medical use. Schedule I includes some substances that are exceptionally dangerous (including heroin and LSD) and some that are less dangerous (including marijuana, which is less dangerous than some substances in other schedules).” When asked point blank, what’s more dangerous Oxy or Marijuana DEA says “Oxy.”

Robert Capecchi, Director of Federal Lobbying at the Marijuana Policy views medical marijuana legalization as a means to an opioid end as well as fiscal no brainer with far reaching benefits.

“Ending marijuana prohibition will allow licensed businesses to cultivate, distribute, and sell marijuana to adults. Unlike the criminal market, a legal and regulated market means products are pure, tested and labeled, sales are taxed, and business disputes are resolved in the courts, not with violence. Additionally, there is promising evidence to suggest that legal access to medical marijuana reduces the rates of opioid overdoses and the reliance on prescription pain killers.”

Foregone Conclusion?

Prohibition’s end could very well be right around the corner, but would we want it in the form of legal medical marijuana at a Walgreens near you? August 11th’s ruling was either one of many dominos in the quest for the monopolization of cannabis or just a pessimistic idea based off of history repeating itself. Regardless of which reality we are presently in, it doesn’t hurt to try and connect the dots, but if I can leave you with one last thing it’s the number 6630507. In case you’re wondering that’s the United States patent # they filed for cannabis in 2003 citing “multiple therapeutic uses.” I can only postulate why they did that….

Regards,

Jason Spatafora

Drug War

The following is an article highlighting what is in our opinion the best Marijuana Stocks / Cannabis Stocks to Watch in 2017 & Beyond.

Earlier this year we covered the market for marijuana stocks post Trump and many of these marijuana stocks have continued to see progress over the time since. Now that we’re finally through the transitional period, it’s time to look ahead at marijuana stocks to watch in 2017 and even beyond. Who would have thought this industry would have come this far, let alone open up the doors to an entirely new and evolving sector.

In fact, according to new research, North American sales are projected to top $20.2 billion by 2021. Marijuana sales in North America grew by an unprecedented 30% in 2016 to $6.7 billion as the legal market expands in the U.S. and Canada, according to a report from Arcview Market Research. So, it’s hard not to find the best marijuana stocks to watch this year and in the years to come.  Several we have watched, mentioned, reported on, and reviewed very recently with favorable market activity in play.

First and foremost, mCig, Inc. (MCIG) is a company we’ve watch grow immensely over the last few months.  Since it was trading around 2 and a half cents in September, MCIG has seen highs of as much as $0.505.  The stock has been upholding a channel roughly between $0.30 and $0.40 for the last few weeks and multiple announcements show, in our opinion, that company’s focus on really building shareholder value including triple digit sales growth, canceling 20 million shares  and converting another 60 million shares into preferred that also carry with it a 2 year lock up.  The company has also announced that it will be reporting on its “record financial growth numbers and cost basis investments; to include, Vapolution, VitaCBD, Omni Health (OTC PINK: OMHE,) Agri-Contractors, and other strategic partnerships.”
The Green Organic Dutchman Holdings Ltd. (TGOD) comes onto this list following the roll-out of our previous coverage on now public company, Emblem Corp (EMMBF). Emblem was one of the most anticipated offerings that has come out of Canada in the last few months.  For TGOD, besides being licensed under the access to cannabis for medical purposes regulations (ACMPR) to cultivate medical marijuana, TGOD has some big names behind it from a financing front including familiar faces from the Emblem & Organigram camps.

In addition to this, the company has 1,000 kg current annual indoor operating capacity as well as a newly acquired property coming in at 75 acres, which adjoins the current facility. The planned IPO of TGOD is in October, more details here.

We looked at OWC Pharmaceutical Research Corp.  (OWCP).  This was trading around $0.95 and recent trading activity has seen this hit as high as $3.23.  The company has most recently been adding to its advisory board.  Both Dr. Sharon Rozenblat and Ms. Miriam Sani, MSc Eng. Dr. Rozenblat will be overseeing the completion of the pre-clinical safety studies on the Company’s treatment for psoriasis, which commenced in November 2016 and Sani is the CEO and owner of “Shefa Amirim” Ltd, which provides regulatory affairs and clinical consultation services for early-stage start-ups in various medical fields. The company itself focuses on two things: 1. medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines and 2. OWCP is developing unique delivery systems for the effective delivery and dosage of medical cannabis.

Rocky Mountain High Brands (RMHB) is another company we’ve watched since the days it was called Totally Hemp Crazy and ever since, we’ve seen this company grab attention of the market.  The company specialized in hemp infused beverages and more recently an alkaline water called Eagle Spirit, which was issued a trademark on Feb 22. Aside from this, the company has been implementing a partnership strategy, enhancing its internal fulfillment operations, as well as making it a known presence at industry conventions.  As of Wednesday 2-22-2017, shares of Rocky Mountain High had hit highs of $0.118.

Advantis Corp. (ADVT) was a company we started watching last summer and since the beginning of the year, we picked back up on it.  There’s enough going on here in our opinion to take notice of including the recent announcements that the company has taken steps to become a fully-reporting public company as well as launched distribution of topical cannabis roll-on and Tinctures to treat pain conditions. This also comes as the company has begun to further expand on its overall product offering so just like we cited at first “way back when” with Totally Hemp Crazy, we think that ADVT could be another company to follow during its infancy.  Since we picked back up on this, we’ve also watched as ADVT climbed from around $0.005 to highs of $0.035 during the last full week of February.

UbiquiTECH Software Corp. (UBQU) was another company we mentioned a few months ago and saw it promptly run from under $0.015 to highs of $0.04.  Of course the market saw pull back but now the new price channel might be hovering closer to 0.02 than 0.01 where it was at late last year.  Fundamentally speaking, the company has announced several new CBD products, paying down thousands of dollars in debt, as well as realizing significant revenue growth of 35% as well as an increase in earnings of 840% compared to that of 2015.  Compared to the company’s annual revenue of $3,493,113, UBQU saw a recognizable jump from the 4th quarter were 35% of the company’s total revenues for the year.  Further UBQU’s last 3 quarters leading up to the most recent filing show quarter over quarter revenue growth and report a net income for the year of over $330,000

Aurora Cannabis Inc. (TSXV: ACB) (OTCQB: ACBFF) made our list a few months ago and it has kept its spot especially considering the move for Canada’s legalization. The company’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations and operates a 55,200 square foot, expandable, state-of-the-art production facility in Mountain View County, Alberta, Canada. In addition to partnership and collaboration deals with the like of companies like Radient Technologies (RTI.V), this company has also obtained significant financial contributions through its bought deal private placement with a syndicate of underwriters led by Canaccord Genuity Corp. for aggregate gross proceeds to Aurora of $60,007,500.

Other Canadian marijuana stocks to watch include Canopy Growth (WEED.TO), which just announced that it has entered into a memorandum of understanding with Namaste Technologies Inc. “to define the intention of Namaste and Canopy to expand their respective market positions by seeking to form multi-point working arrangements and exploring the development of new delivery devices for the consumption of cannabis.”

Namaste’s database consists of approximately 300,000 customers that generate upwards of 600,000 site visits monthly. Namaste also has 26 e-commerce retail stores in 20 countries. We watch now in the midst of all of the developments as Canopy has grown from a stock trading under $3 to today’s price of more than $12/share.

Future Farm (CSE: FFT) (OTCQB: FFRMF) formerly AGSTF, this company is something we’ve covered from very early on.  This company has been aggressively expanding into the marijuana space.  The Company’s business model includes developing and acquiring technologies that will position it as a leader in the evolution of Controlled Environment Agriculture (CEA) for the global production of various types of plants. Future Farm provides scalable, indoor CEA systems that utilize minimal land, water and energy regardless of climate, location or time of year and are customized to grow an abundance of crops close to consumers, therefore minimizing food miles and its impact to the environment.  We began following this at $0.137 and this week it has managed to hit highs of $0.50; a solid run of 265% so far and could certainly be something to be watching into 2017.

Similar to Aurora, Aphria, Inc. (APH.V) (APHQF) has entered into an agreement with Clarus Securities to which the Underwriters have agreed to purchase, on a “bought deal” basis, 10,000,000 Common Shares of the Company at a price of C$5.00 per Common Share for aggregate gross proceeds to the Company of C$50,000,000. This is expected to close on or about February 24 of this year. The company also recently received approval to jump from the TSX Venture Exchange to list on the TSX and depending on meeting certain conditions, is expected to be finalized on or before the TSX imposed May 3rd, 2017 deadline. The stock on the US exchange and the Canadian exchange has been on an uptrend since last March.

0 1285

*BIG NEWS FROM $VNNYF*
Company To Acquire 65% of Health Canada and FDA Licensed Laboratory

 

Vinergy Resources Ltd. (CSE:VIN)(OTCQB:VNNYF) in conjunction with its proposed acquisition of MJ BioPharma (announced December 14, 2016) is pleased to announce that, as a part of the Company’s strategy to develop products that test and identify specific cannabinoid isolates for targeted therapeutic purposes it has signed a binding Letter of Intent (“LOI”) to acquire 65% of Biolennia Laboratories Inc.!

This is a fantastic acquisition for us and supports our entire product line and R&D initiatives moving forward. Our technical expertise in drug testing, extractions, and formulas containing CBD, Terpene, THC and other botanicals is continually being furthered. We have a remarkable team. We feel strongly that science based products formulated from extracts and derivatives that are properly dosed and manufactured in GMP environments to ensure consistency and safety for all customers whether they be recreational or medical users, is the future of the cannabis industry,” MJ BioPharma CEO Kent A. Deuters.

 


*Click Here Now To Read Full PR*


$UBQU Announces New Third Party Verification of its CannazALL Products


Ubiquitech Software Corp. ( OTC PINK : UBQU ), through its subsidiary HempLife Today™, is announcing a very important step in streamlining a new process for verification of its CannazALL™ CBD products to help boost sales and greater overall consumer trust in its popular CannazALL™ brand.

Under this new development all CannazALL™ CBD products will continue to be internally and third-party tested and a new retrieval process will be created so that new and existing consumers have additional clarification on the quality of the products they are ordering and consuming. The company believes that giving consumers easier access to this information will help boost consumer confidence which should naturally result in additional sales, repeat orders, and a boost in revenues.


Click Here To View Full Press Release



$MCIG Announces New Date for Conference Call

 

mCig Inc. (MCIG) announced today that, due to the closing of a significant transaction this week, management has elected to postpone the scheduled shareholder call one week, which will now be held on Tuesday, March 7, 2017 at 4:30 P.M. Eastern Time (ET). MCIG will discuss our outstanding third quarter numbers, the recent developments with our cost basis investments, and our future growth plans and vision. The event will include a panel discussion with the MCIG management team.


Click Here To Read Full PR


 

CBD Offers A Natural Anti-anxiety, Antipsychotic, And Anti-epileptic Effect

It seems people are searching for peace, tranquility, and a sense of overall well being these days. There is so much anxiety in combination with the instability of the the economy, government, the weather, and life in general is overwhelming for many of us. The pursuit is always to find that natural high, whether from yoga, meditation, running, or anything that gets the blood moving and oxygen flowing...[continue reading]


Click Here Now To Read Full Article


Pursuant to an agreement between MAPH and Ubiquitech Software Corp., we were hired for a period beginning November 11 2016 and ending May 11, 2017 to publicly disseminate information about (UBQU) including on the Website and other media including Facebook and Twitter. We are being paid $0 (CASH) for or were paid “10 million” shares of restricted common shares. Pursuant to an agreement between MAPH and Vinergy Resources, we were hired for a period of 2 months to publicly disseminate information about (VNNYF) including on the Website and other media including Facebook and Twitter. We are being paid $120,000 (CASH) for or “ZERO” shares of restricted or unrestricted common shares. We own zero shares of (VNNYF) which we purchased in the open market.MAPH owns 2 million restricted common shares of MCIG Inc. We may buy or sell additional shares of (UBQU,MCIG,VNNYF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements